SEC Filing Summary: Heatwurx, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Heatwurx, Inc. on September 30, 2014. The report details a material modification to the rights of security holders approved by the Board of Directors on the same date. Note: The filing identifies the registrant as Heatwurx, Inc., not Processa Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance action regarding warrant terms.
Material Changes
The Board of Directors approved an amendment to all outstanding Series D Warrants to extend their expiration dates. Previously, warrants from the June 2013 unit offering were set to expire on October 1, 2014, and those from the September 2013 offering were set to expire on January 15, 2015. Under the new terms, all outstanding Series D Warrants will now expire on October 1, 2015.
Guidance, Outlook, and Risks
The filing cites Section 12(c) of the Warrant to Purchase Common Stock, which grants the company the sole discretion to extend the expiration date one or more times. No financial guidance, management commentary on operations, or specific risk factors were disclosed in this document.
Key Facts for Investor Verification
- Confirm the total number of outstanding Series D Warrants affected by the extension.
- Verify the exercise price and conversion terms of the Series D Warrants.
- Check for any subsequent filings regarding the exercise or expiration of these warrants by October 1, 2015.
- Clarify the relationship between Heatwurx, Inc. and Processa Pharmaceuticals, Inc., given the discrepancy in the provided metadata versus the filing text.